Beyond the Sequence
Beyond the Sequence
复制标题
DOI：
10.1089/clinomi.02.02.05
复制
发表时间：
2015-09
期刊：
影响因子：
--
通讯作者：
C. Anderson
中科院分区：
文献类型：
--
作者：
C. Anderson
克里斯安德森无论他们关注的是单个基因的突变，还是两个或多个基因组合的突变，今天的肿瘤学家都期待着利用基因组信息来更精确地靶向和治疗癌症。但是，随着越来越多的研究人员深入研究发现哪些基因突变与特定的癌症亚型有关，或者哪些药物在对抗由其特征识别的癌症方面最有效，他们开始测试其信息工具的局限性计算平台，信息包和分析算法。这些数字因素正在推动（有时也会阻碍）当今提高癌症治疗精度的许多挑战与基因测序产生的数据的复杂性以及已发表文献中包含的大量生物医学信息直接相关，这些信息详细介绍了癌症根源和药物的新发现，最有效的治疗方法。
Chris Anderson hether they are concerned with a mutation of a single gene, or mutations in a combination of two or more genes, today’s oncologists look forward to using genomic information to more precisely target and treat cancer. But as more and more researchers delve into the work of discovering which genetic mutations are associated with specific sub-types of cancer, or which drugs are most effective in fighting the cancers identified by their signatures, they begin to test the limits of their informational tools—computing platforms, informatics packages, and analytic algorithms. These digital factors are driving (and sometimes hindering) advances in developing more precise and targeted therapies for individual cancer patients.Many of today’s challenges to increasing the precision of cancer treatment are directly related to both the complexity of data generated by genetic sequencing and the sheer volume of biomedical information contained in the published literature detailing new discoveries in the root causes of cancer and the drugs and therapies that most effectively treat it.